KLSC Statement: President Trumps Visit to Kentucky

Kentucky Life Sciences Council (KLSC) appreciates this administration visiting Ohio and Kentucky to highlight the efforts our region is making in biopharmaceutical innovation.  We shares their concerns about access and affordability of prescription medications. Rising insurance costs are a burden on patients and families, and KLSC strongly supports policies that meaningfully lower out-of-pocket costs, like the recent PBM reform that President Trump signed into law. However, KLSC strongly opposes initiatives that will restrict access and harm innovation, such as government price controls or the so called Most Favored Nation status. The United States leads the world in healthcare innovation because it has maintained an environment that rewards innovation. Policies that enable more government price setting will ultimately cost patients the next generation of cures.